Glycogen synthase kinase-3 levels and phosphorylation undergo large fluctuations in mouse brain during development

Bipolar Disorders

Volumn 14, Issue 8, 2012, Pages 822-830

  Beurel, Eléonore ^a   Mines, Marjelo A ^a   Song, Ling ^a   Jope, Richard S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Brain development; Fluoxetine; Glycogen synthase kinase 3; Lithium; Mood disorders

Indexed keywords

FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FEMALE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; FEMALE; FLUOXETINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; LITHIUM CHLORIDE; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84869818168     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12023     Document Type: Article

References (37)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
2. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007; 64: 1032-1039.
3. Rohde P, Silva SG, Tonev ST et al. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. Arch Gen Psychiatry 2008; 65: 447-455.
4. Andersen SL, Teicher MH. Stress, sensitive periods and maturational events in adolescent depression. Trends Neurosci 2008; 31: 183-191.
5. Grimes CA, Jope RS. The multi-faceted roles of glycogen synthase kinase-3β in cellular signaling. Prog Neurobiology 2001; 65: 391-426.
6. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Frontiers Mol Neurosci 2011; 4: 40-49.
7. Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011; 4: 15.
8. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Progress Neurobiol 2006; 79: 173-189.
9. Woodgett JR. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 281-290.
10. Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3 (GSK3). Trends Biochem Sci 2004; 29: 95-102.
11. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
12. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
13. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium. Neuropharmacol 2002; 43: 1158-1164.
14. Jope RS. Lithium and GSK3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-443.
15. Li X, Zhu W, Roh M-S, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29: 1426-1431.
16. Li X, Rosborough K, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007; 10: 7-19.
17. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005; 57: 533-542.
18. Roh MS, Seo MS, Kim Y et al. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 2005; 39: 353-360.
19. Okamoto H, Voleti B, Banasr M et al. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry 2010; 68: 521-527.
20. Beaulieu JM, Zhang X, Rodriguiz RM et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008; 105: 1333-1338.
21. Beaulieu JM, Sotnikova TD, Yao WD et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099-5104.
22. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-390.
23. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781-784.
24. O'Brien WT, Harper AD, Jove F et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24: 6791-6798.
25. O'Brien WT, Huang J, Buccafusca R et al. Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 2011; 121: 3756-3762.
26. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
27. Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 2006; 7: 1399-1409.
28. Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Frontiers Mol Neurosci 2011; 4: 16-26.
29. Leroy K, Brion JP. Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J Chem Neuroanat 1999; 16: 279-293.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem 1976; 72: 248-254.
31. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
32. Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3β and mood stabilizing agents. J Neurochem 2002; 82: 75-83.
33. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
34. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88-109.
35. Polter A, Beurel E, Yang S et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010; 35: 1761-1774.
36. McNeill H, Woodgett JR. When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol 2010; 11: 404-413.
37. Yanfeng W, Saint-Jeannet JP, Klein PS. Wnt-frizzled signaling in the induction and differentiation of the neural crest. BioEssays 2003; 25: 317-325.